I'm LongbridgeAI, I can summarize articles.Adma Biologics (ADMA) fell 4.05% this week to close at $9.23 on Friday, while the S&P 500 slipped 0.8%, leaving the stock about 3.25 percentage points behind the benchmark. The four-session week opened at $9.51 on Tuesday and hit a weekly high of $9.65 before fading into Friday’s low of $9.195, a classic rally that gave way to selling pressure.
The Week
Adma Biologics (ADMA) fell 4.05% this week to close at $9.23 on Friday, while the S&P 500 slipped 0.8%, leaving the stock about 3.25 percentage points behind the benchmark. The four-session week opened at $9.51 on Tuesday and hit a weekly high of $9.65 before fading into Friday’s low of $9.195, a classic rally that gave way to selling pressure. There were no major business catalysts; the only news item was a law firm’s investigation into the board’s fiduciary duties, a governance-related matter.
Analyst Ratings
ADMA currently has 4 covering firms: 2 rate it buy, 1 overweight and 1 hold, with no underweight or sell ratings. The consensus rating is buy, and the consensus target of $17 sits about 84.2% above the latest price of $9.23. Targets range from $12 to $21, showing meaningful dispersion. Among 506 biotechnology companies, ADMA’s rating rank is 308, placing it in the lower-middle tier.
The Week Ahead
ADMA has no earnings of its own scheduled next week, so the focus shifts to US macro data. The New York Fed manufacturing index lands on Tuesday 15 September, followed on Wednesday 16 September by retail sales, retail sales ex-autos, import prices and the NAHB housing market index. These releases will shape the broader risk appetite for biotech names and are worth tracking alongside ADMA.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.